Guardant Health Raises 2026 Revenue Outlook After 44% Q2 Surge
GH has more than doubled off its 52-week low of $40.355.
Summary
Guardant Health lifted its full-year revenue guidance to $1.34B-$1.36B, above the $1.31B consensus, after Q2 revenue jumped 44% to $335M, beating estimates by $20.8M. The raise follows the Q2 8-K filed yesterday and reflects accelerating test volumes—oncology revenue up 38% and screening revenue surging 257%. The stock added 6.1% Friday, extending its year-to-date gain to nearly 60%. Despite a wider GAAP loss from commercial investments, the top-line momentum and raised outlook signal strong demand for its liquid biopsy and screening tests. Watch for the 424B prospectus supplement tied to the July 30 S-3ASR shelf, which could indicate capital-raising plans.
At the time of this announcement, GH was trading at $162.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5B. The 52-week trading range was $40.36 to $176.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.